To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
ORIGINAL RELEASE: October 1, 2020
EXPIRATION: October 31, 2021
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
CLICK HERE TO PROCEED TO PROGRAM
LEARNING METHOD AND MEDIUM
This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.
Topical corticosteroids, including dexamethasone, difluprednate, fluorometholone, loteprednol, and prednisolone, are potent anti-inflammatory medications that are prescribed for a wide range of indications in ophthalmology. Their uses include control of inflammation associated with cataract and other ocular surgeries, dry eye disease, eyelid disorders, allergic eye conditions, and anterior uveitis. New topical corticosteroid products have recently been approved, including loteprednol etabonate in a submicron particle formulation. Additionally, some topical corticosteroid products have recently or will soon become available as generic versions. The desired results of this educational activity are for ophthalmologists to help their patients with a variety of inflammatory conditions achieve better outcomes.
This educational activity is intended for ophthalmologists.
Upon completion of this activity, participants will be better able to:
- Discuss the efficacy of newer topical corticosteroids to control ocular inflammation
- Explain the formulation characteristics and safety of newer topical corticosteroids to control ocular inflammation
- Identify optimal strategies for control of postoperative inflammation for patients undergoing ophthalmic surgery
- Identify optimal strategies for control of inflammation for patients with ocular inflammatory disease such as dry eye
- Use appropriate strategies to discuss the differences between generic and brand name anti-inflammatory agents
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.
AMA CREDIT DESIGNATION STATEMENT
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.
DISCLOSURE POLICY STATEMENT
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Eric D. Donnenfeld, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; Kala Pharmaceuticals; and Oculis.
Marguerite B. McDonald, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Akorn, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; BlephEx; Dompé US, Inc; GlaxoSmithKline; Johnson & Johnson Vision Care, Inc; OCULUS, Inc; OcuSOFT Inc; Orca Surgical; Quidel Corporation; Strōma Medical Corporation; TearLab Corporation; and Visus Therapeutics.
I. Paul Singh, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Ellex; Glaukos Corporation; Imprimis Pharmaceuticals, Inc; Ivantis Inc; New World Medical, Inc; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; Reichert, Inc; Sight Sciences; and Sun Pharmaceutical Industries, Inc.
Elizabeth Yeu, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Aurea Medical; Avedro, Inc; Avellino Labs; Bausch & Lomb Incorporated; Beaver-Visitec International; Bio-Tissue; BlephEx; Bruder Healthcare; Cassini Technologies; CorneaGen; Dompé US, Inc; EyePoint Pharmaceuticals; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; LENSAR, LLC; Melt Pharmaceuticals; Merck & Co., Inc; Minosys Cellular Devices Inc; Novartis Pharmaceuticals Corporation; Ocular Science; Ocular Therapeutix, Inc; OCuSOFT Inc; Omeros Corporation; Oyster Point Pharma, Inc; ScienceBased Health; Sight Sciences; Sun Pharmaceutical Industries, Inc; Surface Pharmaceuticals Inc; TearLab Corporation; Topcon Medical Systems, Inc; Valeant; and Zeiss; Contracted Research: Alcon; Bio-Tissue; Cassini Technologies; Ocular Science; Topcon; and TearLab Corporation; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Avellino Labs; BlephEx; CorneaGen; Melt Pharmaceuticals; Minosys Cellular Devices Inc; and Oyster Point Pharma, Inc.
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE
Priti Batta, MD, has no relevant commercial relationships to disclose.
EDITORIAL SUPPORT DISCLOSURES
Cheryl Guttman Krader; Melissa Carter, MS; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
CME Provider Contact Information
For questions about this activity, call 917-270-7571.
TO OBTAIN AMA PRA CATEGORY 1 CREDIT ™
To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Please take the post test and evaluation online. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Bausch & Lomb Incorporated, or Ophthalmology Times.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 218 CLICK HERE TO PROCEED TO PROGRAM